Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 9

Results For "CIPLA"

120 News Found

Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy
People | April 17, 2025

Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy

Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio


Shaik Barak Tulla joins Sun Pharma as Sr. VP
People | April 14, 2025

Shaik Barak Tulla joins Sun Pharma as Sr. VP

Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla


Neuland appoints Parag Deshmukh as SVP – Head of Manufacturing
People | March 24, 2025

Neuland appoints Parag Deshmukh as SVP – Head of Manufacturing

Prior to joining Neuland, Deshmukh held several key positions at Cipla


Abbott India appoints Prithwish K Banerji as Commercial Director - Women’s Health, Metabolics and International Business
People | January 03, 2025

Abbott India appoints Prithwish K Banerji as Commercial Director - Women’s Health, Metabolics and International Business

Prithwish has close to 28 years of experience in a Commercial role


Senores Pharmaceuticals IPO lists at 53% premium
News | December 31, 2024

Senores Pharmaceuticals IPO lists at 53% premium

The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline


Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories
News | November 28, 2024

Senores Pharmaceuticals launches Ivermectin Tablets in US with Dr. Reddy's Laboratories

The product will be marketed by Dr. Reddy's


Akums appoints Shantanu R Chobhe as Corporate Quality Assurance Head
People | September 05, 2024

Akums appoints Shantanu R Chobhe as Corporate Quality Assurance Head

Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry


Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
News | May 14, 2024

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024